SynthesisBMC infectious diseases2026
Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety of antiretroviral therapy(ART) regimens based on tenofovir(TDF) + lamivudine(3TC) + efavirenz(EFV) in patients co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV), thereby providing evidence-based support for clinical treatment decision-making.
methodsRelevant studies published from database inception to March 2025 were systematically retrieved from the CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library databases. The revised Risk of Bias tool version 2 (ROB2) was used to assess study quality, and all meta-analyses were performed using Stata 18 software.
resultsA total of 31 randomized controlled trials (RCTs) involving 2124 participants and 12 treatment interventions were included, with four outcome measures evaluated. The network meta-analysis demonstrated that the TDF + 3TC + EFV triple therapy regimen was superior to the other evaluated regimens in achieving higher HBV DNA and HIV RNA negative conversion rates. In addition, TDF+ 3TC + EFV demonstrated greater efficacy than zidovudine(AZT) + 3TC + EFV in increasing CD4 + lymphocyte counts. The surface under the cumulative ranking curve (SUCRA) analysis indicated that TDF + 3TC + EFV ranked highest in terms of efficacy. Regarding safety, several studies reported various types of adverse events. However, no statistically significant differences were observed among the treatment groups.
conclusionBased on the currently available evidence, this network meta-analysis suggests that the TDF + 3TC + EFV triple regimen demonstrates superior efficacy across multiple outcome measures in patients with HIV/HBV co-infection. Nevertheless, owing to the inherent limitations of the included studies, further high-quality studies are required to confirm its role as a preferred therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.